Elevation Oncology's Upcoming Investor Engagements
Elevation Oncology, Inc. (NASDAQ: ELEV) is making waves in the oncology sector with its exciting pipeline of selective cancer therapies. The company is geared up to participate in significant investor conferences that are scheduled for March. These events highlight the company’s commitment to presenting its innovative approaches and engaging with investors.
Key Conferences on the Horizon
The first major engagement is slated for the TD Cowen 45th Annual Health Care Conference. Here, management will partake in a fireside chat on a specific Tuesday in March, providing insights and updates related to their work and findings. This event will take place at 9:10 AM ET.
Following Conference Events
Shortly thereafter, Elevation Oncology will be at the Leerink Global Biopharma Conference, continuing its dialogue with the investment community. This fireside chat is scheduled for 8:40 AM ET on another Tuesday in March. The participation in these conferences underscores the company's transparency and dedication to keeping stakeholders informed.
Access to Live Webcasts
For those unable to attend these events in person, Elevation Oncology is ensuring that the discussions are accessible. A live webcast will be available on the company’s Investor Relations website. This offers an excellent opportunity for investors to catch up on what’s being shared.
About Elevation Oncology
Elevation Oncology stands out as a pivotal player in the cancer treatment industry. With its focus on developing therapies that specifically target unmet medical needs in solid tumors, the company is leveraging advanced antibody-drug conjugate (ADC) technology. Their pipeline includes promising candidates like EO-3021, aimed at treating patients with major gastric and gastroesophageal cancers expressing Claudin 18.2. Currently, EO-3021 is undergoing evaluation in Phase 1 trials, showcasing the company’s innovative spirit and commitment to advancing cancer care.
Focus on HER3-targeting Therapies
Elevation Oncology is also developing EO-1022, a HER3 ADC. This targeted therapy aims to provide effective treatment options for patients living with solid tumors that express the HER3 marker. The dual focus on Claudin 18.2 and HER3 highlights the company’s strategy of targeting specific cancer mechanisms, which may lead to better patient outcomes and lower side effects.
Investor and Media Relations
Gracie Tong serves as the Senior Director of Investor Relations and Corporate Communications for Elevation Oncology. She plays an integral role in facilitating communication between the company and its investors as well as the media.
Frequently Asked Questions
What is Elevation Oncology focused on?
Elevation Oncology is dedicated to developing selective therapies for treating solid tumors, particularly those with significant unmet medical needs.
What events will Elevation Oncology participate in?
Elevation Oncology will participate in the TD Cowen 45th Annual Health Care Conference and the Leerink Global Biopharma Conference in March.
How can investors access the conference webcasts?
Investors can access live webcasts of the fireside chats on the company's Investor Relations website, ensuring they stay updated.
What are the highlights of Elevation Oncology's pipeline?
Key treatments include EO-3021, which targets Claudin 18.2, and EO-1022, which focuses on HER3 in solid tumors.
Who manages investor relations at Elevation Oncology?
Gracie Tong is the Senior Director responsible for managing relations with investors and media at Elevation Oncology.
